Sarepta Therapeutics Inc. (SRPT) Receives “Outperform” Rating from Wedbush
Wedbush restated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note published on Tuesday morning. The firm currently has a $66.00 target price on the stock.
Several other equities analysts have also issued reports on the company. Cowen and Company upgraded Sarepta Therapeutics from a market perform rating to an outperform rating and set a $64.00 target price on the stock in a research note on Tuesday. Oppenheimer Holdings Inc. lifted their target price on Sarepta Therapeutics from $60.00 to $76.00 in a research note on Monday. JMP Securities upgraded Sarepta Therapeutics to an outperform rating and lifted their target price for the company from $10.00 to $60.00 in a research note on Monday. Jefferies Group upgraded Sarepta Therapeutics from an underperform rating to a hold rating and set a $50.00 target price on the stock in a research note on Monday. Finally, RBC Capital Markets upgraded Sarepta Therapeutics from a sector perform rating to an outperform rating in a research note on Monday. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Tuesday. The stock has a 50 day moving average of $28.17 and a 200 day moving average of $21.37. The company’s market cap is $2.67 billion. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. Equities research analysts predict that Sarepta Therapeutics will post ($4.98) EPS for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at $2,309,490. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of SRPT. National Planning Corp boosted its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Rhumbline Advisers boosted its stake in Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock worth $891,000 after buying an additional 721 shares during the period. Teacher Retirement System of Texas boosted its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. First Allied Advisory Services Inc. boosted its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Finally, LGL Partners LLC boosted its stake in Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.